Nifurtimox

Revision as of 16:57, 10 September 2019 by ClaireLewis (talk | contribs) (→‎Comments)

Administration

  • Type: Antiparasitic
  • Dosage Forms:
  • Routes of Administration: PO
  • Common Trade Names: Lampit

Adult Dosing

  • 8-10 mg/kg/day PO divided q6-8hr for 90-120 days

Pediatric Dosing

  • 1-10 years: 15-20 mg/kg/day PO divided q8hr
  • 11-16 years: 12.5-15 mg/kg/day PO divided q8hr x90 days

Special Populations

Pregnancy Rating

  • Unknown risk, no human data available

Lactation risk

  • Unknown

Renal Dosing

  • Contraindicated in renal impairment

Hepatic Dosing

  • Contraindicated in hepatic impairment

Contraindications

  • Allergy to class/drug
  • Active or history of peripheral neuropathy
  • Active or history of seizures or cerebral impairment, behavioral disorders, or psychoses
  • Hepatic impairment
  • Renal impairment

Adverse Reactions

Serious

  • Seizures
  • Pleural effusion

Common

  • Anorexia (can be significant and limit completion of therapy)
  • Ataxia, paresthesia, polyneuritis, tremor
  • Depression, fatigue, sleep disorder, weakness
  • Headache
  • Memory impairment
  • Rash, pruritic dermatitis
  • Gastralgia, vomiting
  • Myalgia
  • Pulmonary infiltrates

Pharmacology

  • Half-life: 2.95 +/- 1.19 hr
  • Metabolism: Hepatic
  • Excretion: Urinary

Mechanism of Action

  • Inhibits trypanothione reductase, a parasite-specific antioxidant defense enzyme

Comments

  • Investigational status in the US[1]

See Also

References

  1. ↑ https://reference.medscape.com/drug/lampit-nifurtimox-342663#0
Retrieved from "https://www.wikem.org/w/index.php?title=Nifurtimox&oldid=227793"
Authors: